Recognizing and treating depression in children and adolescents (Q44246465)

1 December 2017

Recognizing and treating depression in children and adolescents (English)

1 reference

1 December 2017

1 reference

Julie A Dopheide

1

1 reference

PubMed ID

16434782

1 December 2017

language of work or name

1 reference

1 February 2006

1 reference

American Journal of Health-System Pharmacy

1 December 2017

1 reference

1 December 2017

63

1 reference

1 December 2017

233-243

1 reference

1 December 2017

3

1 reference

Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002.

1 December 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Antidepressants and pediatric depression--the risk of doing nothing

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: an evidence-based medicine review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Outpatient treatment of child and adolescent depression in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Quality of care for medicaid-covered youth treated with antidepressant therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Prevalence and development of psychiatric disorders in childhood and adolescence

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Prevalence of and risk factors for depressive symptoms among young adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Natural course of adolescent major depressive disorder in a community sample: predictors of recurrence in young adults

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Preschool major depressive disorder: preliminary validation for developmentally modified DSM-IV criteria.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Age effects on antidepressant-induced manic conversion

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Treatment guidelines for children and adolescents with bipolar disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Drug-drug interactions in pediatric psychopharmacology

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

First episode of depression in children at low and high familial risk for depression

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Vulnerability and resiliency to suicidal behaviours in young people

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Volumetric reduction in left subgenual prefrontal cortex in early onset depression.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Growth hormone secretion in children and adolescents at high risk for major depressive disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Childhood trauma associated with smaller hippocampal volume in women with major depression.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Amygdala and hippocampus volumes in pediatric major depression.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

A case-control and family-based association study of the 5-HTTLPR in pediatric-onset depressive disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Suicidal thoughts and attempts among adolescents: a longitudinal 8-year follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Relationship Between Antidepressant Medication Treatment and Suicide in Adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

The relationship between antidepressant medication use and rate of suicide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Children with prepubertal-onset major depressive disorder and anxiety grown up.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Which depressed patients respond to cognitive-behavioral treatment?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

A family study of major depressive disorder in a community sample of adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Open trial of interpersonal therapy in adolescents with moderate to severe major depression: effectiveness of novice IPT therapists

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Nontricyclic antidepressants: current trends in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Pharmacological management of treatment-resistant pediatric depression

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Case study: nefazodone for juvenile mood disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

The use of tricyclic antidepressants in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Tricyclic antidepressants and cardiac autonomic control in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Antidepressants and the risk of suicidal behaviors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Preliminary data on the relationship between nortriptyline plasma level and response in depressed children

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050264

31 March 2020

Identifiers

DOI

10.2146/AJHP050264

1 reference

release_lvxod4cxfjezzchsz4t2seho4i

1 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lvxod4cxfjezzchsz4t2seho4i

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16434782

1 reference

PubMed ID

16434782